Sareum shares fall following interims and research update

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update.

Shares in AIM-listed Sareum Holdings, the specialist cancer drug discovery business, fell sharply on Monday morning after the company unveiled its half yearly results alongside a research update.

Cash at bank as of December 31st fell 28% to £380,000 and the company reported a loss on ordinary activities after taxation of £269,000. This was less than the reduction reported a year earlier, worth £327,000.

In a separate research update, progress reports were given for a number of the company's programmes showing the level of development that had been measured as well as existing and expected funding options.

Describing the programme known as "VEGFR-3 (FLT4)", the company said: "We have prioritised our research spend on other programmes whilst we investigate grant funding opportunities alongside a partner with the necessary biology expertise to assist us in the progression of this programme."

More detailed updates were given on the company's other programmes. Safety pharmacology studies performed to date on the "Chk1" programme's pre-clinical development candidate were described as "favourable". Oral bio-availability was demonstrated in three species, strengthening its expectation that the compound would be able to be administered via the oral route in future clinical studies.

Head-to-head studies were continuing between two advanced lead molecules as part of the "Aurora+FLT3" with the aim of selecting a pre-clinical development candidate by the middle of the year.

The company further reported that its lead optimisation studies and further compounds had been synthesised with improved potency and selectivity on the "TYK2" programme.

Dr Tim Mitchell, Chief Executive Officer of Sareum, commented: "Our ongoing progress in our research programmes is very encouraging and we continue to discuss the commercialisation of these programmes with a number of interested parties.

"We are also now in a strong position to develop our programmes to later stages, should we so choose, which should mean a greater share of the end rewards and we will continue to consider this aspect alongside our various discussions with potential partners."

Sareum's share price was down 14.67% to 1.60p at 08:44 on Monday.

MF

Recommended

How to be better at selling stocks
Investment strategy

How to be better at selling stocks

There is plenty of advice around about buying stocks, but not so much about when you should sell. John Stepek explains the two key things to know abou…
14 Jan 2022
Share tips of the week – 14 January
Share tips

Share tips of the week – 14 January

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
14 Jan 2022
Fintech: how to profit as technology transforms banking around the world
Share tips

Fintech: how to profit as technology transforms banking around the world

Financial technology – from apps to APIs to the cloud – is rapidly transforming financial services. This will spell doom for some incumbent firms, whi…
14 Jan 2022
Three solid assets to buy for a low interest-rate world
Share tips

Three solid assets to buy for a low interest-rate world

Professional investor Luke Hyde-Smith of the Waverton Real Assets Fund, highlights three alternative investments to diversify your portfolio.
14 Jan 2022

Most Popular

US inflation is at its highest since 1982. Why aren’t markets panicking?
Inflation

US inflation is at its highest since 1982. Why aren’t markets panicking?

US inflation is at 7% – the last time it was this high interest rates were at 14%. But instead of panicking, markets just shrugged. John Stepek explai…
13 Jan 2022
Five unexpected events that could shock the markets in 2022
Stockmarkets

Five unexpected events that could shock the markets in 2022

Forget Covid-19 – it’s the unexpected twists that will rattle markets in 2022, says Matthew Lynn. Here are five possibilities
31 Dec 2021
Interest rates might rise faster than expected – what does that mean for your money?
Global Economy

Interest rates might rise faster than expected – what does that mean for your money?

The idea that the US Federal Reserve could raise interest rates much earlier than anticipated has upset the markets. John Stepek explains why, and wha…
6 Jan 2022